We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
David Baker has served as CEO of Vallon Pharmaceuticals since January 2018.
Previously, Mr. Baker was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that successfully completed a reverse merger with Arcturus Therapeutics in late 2017. Prior to Alcobra, he worked at Shire for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse®, and Vice President, ADHD Marketing.
Prior to Shire, he worked at Merck from 1990-2004 in marketing, sales, market research, and business development. Mr. Baker's therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1 billion each.
Mr. Baker earned a bachelor’s degree in Economics and an MBA in Marketing, both from Duke University.
This speaker's sessions: